Research programme: wnt signalling pathway inhibitors - Bayer HealthCare Pharmaceuticals/OncoMed

Drug Profile

Research programme: wnt signalling pathway inhibitors - Bayer HealthCare Pharmaceuticals/OncoMed

Latest Information Update: 02 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma; OncoMed Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Class Antibodies; Proteins; Small molecules
  • Mechanism of Action Stem cell inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Sep 2014 Preclinical development is ongoing in USA and Germany
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top